natgillin/translations-raw huggingface dataset:
The secondary definition of response required a 4--point or greater improvement on the ADAS-Cog, no worsening on the CIBIC-Plus, and no worsening on the PDS.
Sekundarna opredelitev odziva je zahtevala izboljšanje pri ADAS-Cog za najmanj 4 točke in nobenega poslabšanja pri CIBIC-Plus ter PDS.
Rivastigmine 1 A Pharma oral solution is supplied as 50 ml or 120 ml of a clear, yellow solution (2.0 mg/ml base) in an amber glass bottle with a child-resistant cap, foam liner, dip tube and self aligning plug.
Peroralna raztopina Rivastigmin 1 A Pharma je na voljo v obliki 50 ml ali 120 ml bistre rumene raztopine (2 mg/ml baze), v jantarno obarvani steklenici z za otroke varno zaporko, oblogo iz penaste gume, s kapalnim vložkom in s prilegajočim se zamaškom.
Uncommon (may affect up to 1 in 100 people) • Uneven heartbeat and poor control of movements
Občasni (pojavijo se pri do 1 bolniku od 100) • nepravilen srčni utrip in motnje koordinacije gibov.
Rivastigmine 1 A Pharma should not be given at the same time as metoclopramide (a medicine used to relieve or prevent nausea and vomiting).
Zdravilo Rivastigmin 1 A Pharma se ne sme uporabljati skupaj z metoklopramidom (zdravilo za lajšanje ali preprečevanje slabosti in bruhanja).
Important information about some of the ingredients of Rivastigmine 1 A Pharma
Pomembne informacije o nekaterih sestavinah zdravila Rivastigmin 1 A Pharma
Use Rivastigmine 1 A Pharma oral solution within 1 month of opening the bottle.
Peroralno raztopino Rivastigmin 1 A Pharma porabite v 1 mesecu po prvem odprtju steklenice.
3 years Rivastigmine 1 A Pharma oral solution should be used within 1 month of opening the bottle.
Peroralno raztopino Rivastigmin 1 A Pharma je treba porabiti v enem mesecu po prvem odprtju steklenice.
How to store Rivastigmine 1 A Pharma Contents of the pack and other information
Shranjevanje zdravila Rivastigmin 1 A Pharma Vsebina pakiranja in dodatne informacije
• Take Rivastigmine 1 A Pharma twice a day, in the morning and evening, with food.
• Zdravilo Rivastigmin 1 A Pharma jemljite s hrano dvakrat na dan, zjutraj in zvečer.
Other medicines and Rivastigmine 1 A Pharma
Druga zdravila in zdravilo Rivastigmin 1 A Pharma
The following additional adverse reactions have been observed with rivastigmine transdermal patches: delirium, pyrexia, decreased appetite, urinary incontinence (common), psychomotor hyperactivity (uncommon), erythema, urticaria, vesicles, allergic dermatitis (not known).
Pri uporabi transdermalnih obližev rivastigmina so dodatno opažali še naslednje neželene učinke: delirij, zvišano telesno temperaturo, zmanjšan apetit, urinska inkontinenca (pogosto), psihomotorična hiperaktivnost (občasno), eritem, urtukarija, vezikli, alergijski dermatitis (neznano).
The active substance of Rivastigmine 1 A Pharma is rivastigmine.
Zdravilna učinkovina v zdravilu Rivastigmin 1 A Pharma je rivastigmin.
If you are pregnant, the benefits of using Rivastigmine 1 A Pharma must be assessed against the possible effects on your unborn child. Rivastigmine 1 A Pharma should not be used during pregnancy unless clearly necessary.
V primeru, da ste noseči, je treba pretehtati koristi uporabe zdravila Rivastigmin 1 A Pharma in možne učinke na nerojenega otroka.
Rivastigmine 1 A Pharma 3 mg and 6 mg hard capsules:
Rivastigmin 1 A Pharma 3 mg in 6 mg trde kapsule:
If you have to undergo surgery whilst taking Rivastigmine 1 A Pharma, you should tell your doctor before you are given any anaesthetics, because Rivastigmine 1 A Pharma may exaggerate the effects of some muscle relaxants during anaesthesia.
Če morate v času jemanja zdravila Rivastigmin 1 A Pharma na operacijo, povejte zdravniku, da jemljete Rivastigmin 1 A Pharma, preden dobite kakršnokoli anestezijo, ker lahko Rivastigmin 1 A
Inhibition of butyrylcholinesterase activity in CSF of 14 Alzheimer patients treated by rivastigmine was similar to that of AChE.
v CSF z rivastigminom odvisna od odmerka do največjega preizkušanega odmerka 6 mg, danega dvakrat na dan. Inhibicija aktivnosti butirilholinesteraze v CSF pri 14 bolnikih z Alzheimerjevo boleznijo, zdravljenih z rivastigminom, je bila podobna kot inhibicija AChE.
Some people who have accidentally taken too much Rivastigmine 1 A Pharma have experienced feeling sick (nausea),being sick (vomiting), diarrhoea, high blood pressure and hallucinations.
Rivastigmin 1 A Pharma je prišlo do navzee (slabosti s siljenjem na bruhanje), bruhanja, driske, visokega krvnega tlaka in halucinacij.
How to take Rivastigmine 1 A Pharma
Kako jemati zdravilo Rivastigmin 1 A Pharma
You should not breast-feed during treatment with Rivastigmine 1 A Pharma.
Med zdravljenjem z zdravilom Rivastigmin 1 A Pharma ne smete dojiti.
One of the inactive ingredients in Rivastigmine 1 A Pharma oral solution is sodium benzoate.
Ena od neaktivnih sestavin peroralne raztopine Rivastigmin 1 A Pharma je natrijev benzoat.
One of the excipients in Rivastigmine 1 A Pharma oral solution is sodium benzoate.
Ena od pomožnih snovi peroralne raztopine zdravila Rivastigmin 1 A Pharma je natrijev benzoat.
There is no relevant use of Rivastigmine 1 A Pharma in the paediatric population in the treatment of Alzheimer's disease.
Zdravilo Rivastigmin 1 A Pharma ni primerno za uporabo pri pediatrični populaciji za zdravljenje
• Allergic reaction where the patch was used, such as blisters or skin inflammation If you get any of these side effects, contact your doctor as you may need medical assistance.
• alergijska reakcija na mestu uporabe obliža, kot je pojav mehurjev ali vnete kože.
• Urinary incontinence (inability to retain adequate urine) Uncommon (may affect up to 1 in 100 people)
• urinska inkontinenca (nezmožnost zadrževanja urina).
Package leaflet: Information for the patient Rivastigmine 1 A Pharma 2 mg/ml oral solution
Navodilo za uporabo: Informacije za bolnika Rivastigmin 1 A Pharma 2 mg/ml peroralna raztopina rivastigmin
Adverse reactions in Table 1 and Table 2 are listed according to MedDRA system organ class and frequency category.
V preglednici 1 in preglednici 2 so neželeni učinki navedeni glede na organski sistem po MedDRA
What Rivastigmine 1 A Pharma looks like and contents of the pack
Izgled zdravila Rivastigmin 1 A Pharma in vsebina pakiranja
Each Rivastigmine 1 A Pharma 1.5 mg capsule contains 1.5 mg of rivastigmine.
Ena kapsula Rivastigmin 1 A Pharma 1,5 mg vsebuje 1,5 mg rivastigmina.
Each Rivastigmine 1 A Pharma 4.5 mg capsule contains 4.5 mg of rivastigmine.
Ena kapsula Rivastigmin 1 A Pharma 4,5 mg vsebuje 4,5 mg rivastigmina.
Each Rivastigmine 1 A Pharma 6 mg capsule contains 6 mg of rivastigmine.
Ena kapsula Rivastigmin 1 A Pharma 6 mg vsebuje 6 mg rivastigmina.
even if their signs of illness s are the same as yours.
Njim bi lahko celo škodovalo, čeprav imajo znake bolezni, podobne vašim.
- if you have, or have ever had an active stomach ulcer.
- če imate ali če ste kdaj imeli nepravilen ali počasen srčni utrip, - če imate ali ste imeli aktivno želodčno razjedo,
Rivastigmine 1 A Pharma belongs to a class of substances called cholinesterase inhibitors.
Rivastigmin sodi v skupino učinkovin, ki jih imenujemo zaviralci holinesteraze.
Rivastigmine 1 A Pharma 1.5 mg hard capsules:
Rivastigmin 1 A Pharma 1,5 mg trde kapsule:
Rivastigmine 1 A Pharma 2 mg/ml oral solution rivastigmine (as hydrogen tartrate)
Rivastigmin 1 A Pharma 2 mg/ml peroralna raztopina rivastigmin (v obliki hidrogentartrata)
Each ml contains rivastigmine hydrogen tartrate corresponding to 2mg rivastigmine.
En ml vsebuje rivastigminijev hidrogentartrat, ki ustreza 2 mg rivastigmina.
Each Rivastigmine 1 A Pharma 3 mg capsule contains 3 mg of rivastigmine.
Ena kapsula Rivastigmin 1 A Pharma 3 mg vsebuje 3 mg rivastigmina.
Rivastigmine 1 A Pharma 2 mg/ml oral solution
Rivastigmin 1 A Pharma 2 mg/ml peroralna raztopina
Rivastigmine 1 A Pharma 4.5 mg hard capsules:
Rivastigmin 1 A Pharma 4,5 mg trde kapsule:
Only for carton box: Rivastigmine 1 A Pharma 2 mg/ml
Samo za kartonsko škatlo: Rivastigmin 1A Pharma 2 mg/ml
Only for carton box: Rivastigmine 1 A Pharma 6 mg
Samo za kartonsko škatlo: Rivastigmin 1 A Pharma 6 mg
Only for carton box: Rivastigmine 1 A Pharma 4.5 mg
Samo za kartonsko škatlo: Rivastigmin 1 A Pharma 4,5 mg
Rivastigmine 1 A Pharma is used for the treatment of adult patients with mild to moderately severe Alzheimer's dementia, a progressive brain disorder that gradually affects memory, intellectual ability and behaviour.
To je napredujoča bolezen možganov, ki postopoma prizadene spomin in intelektualne sposobnosti ter vpliva na vedenje bolnika.
How to store Rivastigmine 1 A Pharma
Shranjevanje zdravila Rivastigmin 1 A Pharma
Only for carton box: Rivastigmine 1 A Pharma 1.5 mg
Samo za kartonsko škatlo: Rivastigmin 1 A Pharma 1,5 mg
Only for carton box: Rivastigmine 1 A Pharma 3 mg
Samo za kartonsko škatlo: Rivastigmin 1 A Pharma 3 mg
Rivastigmine 1 A Pharma 6 mg hard capsules: EU/1/09/585/013
Rivastigmin 1 A Pharma 6 mg trde kapsule: EU/1/09/585/013
Rivastigmine 1 A Pharma 4.5 mg hard capsules rivastigmine (as hydrogen tartrate)
Rivastigmin 1 A Pharma 4,5 mg trde kapsule rivastigmin (v obliki hidrogentartrata)
Rivastigmine 1 A Pharma 1.5 mg hard capsules rivastigmine (as hydrogen tartrate)
Rivastigmin 1 A Pharma 1,5 mg trde kapsule rivastigmin (v obliki hidrogentartrata)
- Rivastigmine 1 A Pharma 4.5 mg hard capsules, which contain an off-white to slightly yellow powder, have a red cap and red body, with a white imprint “RIV 4.5 mg” on the body.
- Rivastigmin 1 A Pharma 4,5 mg trde kapsule, ki vsebujejo belkast do rahlo rumen prašek, imajo rdeč pokrovček in rdeče telo kapsule z belim napisom “RIV 4,5 mg”.
Rivastigmine 1 A Pharma 6 mg hard capsules rivastigmine (as hydrogen tartrate)
Rivastigmin 1 A Pharma 6 mg trde kapsule rivastigmin (v obliki hidrogentartrata)
- Rivastigmine 1 A Pharma 1.5 mg hard capsules, which contain an off-white to slightly yellow powder, have a yellow cap and yellow body, with a red imprint “RIV 1.5 mg” on the body.
- Rivastigmin 1 A Pharma 1,5 mg trde kapsule, ki vsebujejo belkast do rahlo rumen prašek, imajo rumen pokrovček in rumeno telo kapsule z rdečim napisom “RIV 1,5 mg”.
Rivastigmine 1 A Pharma 4.5 mg hard capsules: EU/1/09/585/009
Rivastigmin 1 A Pharma 4,5 mg trde kapsule: EU/1/09/585/009
- Rivastigmine 1 A Pharma 3 mg hard capsules, which contain an off-white to slightly yellow powder, have an orange cap and orange body, with a red imprint “RIV 3 mg” on the body.
- Rivastigmin 1 A Pharma 3 mg trde kapsule, ki vsebujejo belkast do rahlo rumen prašek, imajo oranžen pokrovček in oranžno telo kapsule z rdečim napisom “RIV 3 mg”.
- Rivastigmine 1 A Pharma 6 mg hard capsules, which contain an off-white to slightly yellow powder, have a red cap and orange body, with a red imprint “RIV 6 mg” on the body.
- Rivastigmin 1 A Pharma 6 mg trde kapsule, ki vsebujejo belkast do rahlo rumen prašek, imajo rdeč pokrovček in oranžno telo kapsule z rdečim napisom “RIV 6 mg”.
Rivastigmine 1 A Pharma 1.5 mg hard capsules: EU/1/09/585/001
Rivastigmin 1 A Pharma 1,5 mg trde kapsule: EU/1/09/585/001
Rivastigmine 1 A Pharma 3 mg hard capsules: EU/1/09/585/005
Rivastigmin 1 A Pharma 3 mg trde kapsule: EU/1/09/585/005
Rivastigmine 1 A Pharma 3 mg hard capsules rivastigmine (as hydrogen tartrate)
Rivastigmin 1 A Pharma 3 mg trde kapsule rivastigmin (v obliki hidrogentartrata)
There is no relevant use of rivastigmine in the paediatric population in the treatment of Alzheimer's disease.
V pediatrični populaciji ni ustrezne uporabe zdravila Rivastigmin 1 A Pharma za zdravljenje
Sick sinus syndrome
Pri bolnikih z
might reduce its effectiveness.
bi lahko zmanjšalo njihovo učinkovitost.
Date of first authorisation: 18 January 2018
Datum prve odobritve: 18. januar 2018
works by reducing the amount of HIV in your body.
deluje tako, da zmanjša količino HIV v telesu.
once daily.
enkrat na dan.
might be reduced if you take any of the following products.
so lahko zmanjšani, če jemljete katerega od naslednjih zdravil.
Primary (major) PI mutations
Primarne (velike) mutacije PI
has only been used in limited numbers of patients 65 years or older.
je bilo uporabljeno le pri majhnem številu bolnikov starih 65 let ali več.
tablets and how much ritonavir (capsules, tablets or solution) the child must take.
in koliko ritonavirja (kapsule, tablete ali raztopina) mora otrok zaužiti.
might increase the risk of bleeding.
lahko zveča tveganje za krvavitve.
Interaction Geometric mean change (%)
Medsebojnodelovanje Geometričnapovprečna sprememba (%)
twice daily the child must take one dose in the morning, and one dose in the evening.
dvakrat na dan, mora vzeti en odmerek zjutraj in enega zvečer.
TAD Pharma GmbH Heinz-Lohmann-Straβe 5 27472 Cuxhaven Germany
TAD Pharma GmbH Heinz-Lohmann-Straße 5 27472 Cuxhaven Nemčija
600 mg film coated tablets must not be chewed or crushed.
600 mg filmsko obložene tablete se ne smejo žvečiti ali drobiti.
if you are allergic to active substance or any of the other ingredients of this medicine (listed in section 6), if you have severe liver problems.
- če ste alergičnina učinkovino ali katero koli sestavino tega zdravila (navedeno v poglavju 6), - če imate hude težave z jetri.
Hence, the use of creatinine clearance as an estimate of renal elimination capacity may be misleading.
Zato je uporaba očistka kreatinina za oceno obsega izločanja preko ledvic lahko zavajajoča.
Because of both the potential for HIV transmission and the potential for adverse reactions in breast-fed infants, mothers should be instructed not to breast-feed under any circumstances if they are receiving Darunavir Krka d.d..
Zaradi možnosti za prenos okužbe z virusom HIV in možnosti za neželene učinke pri dojenčkih, je treba materam naročiti, naj v nobenem primeru ne dojijo, če jemljejo zdravilo Darunavir Krka d.d..
and a dose adjustment of the antidepressant may be needed.
Morda bo treba prilagoditi odmerek antidepresiva.
is not a cure for HIV infection.
ne ozdravi okužbe z virusom HIV.
with food.
zaužiti s hrano.
400 mg and 800 mg tablets.
400 mg in 800 mg tablete.
is an antiretroviral medicine used in the treatment of Human Immunodeficiency Virus (HIV) infection.
je protiretrovirusno zdravilo, ki se uporablja za zdravljenje okužbe z virusom imunske pomanjkljivosti pri človeku (HIV).
It is therefore important to talk to your doctor if you develop a rash.
Zato je pomembno, da se pogovorite zzdravnikom, če se pri vas pojavi izpuščaj.
darunavir AUC24h ↑ 33% (based on population pharmacokinetic model)
↑ AUC24h darunavirja za 33% (na osnovi populacijskega farmakokinetičnega modela))
These active substances include e.g.:
Med te učinkovine sodijo npr.:
With HIV-1 clade Type B
S podtipom HIV-1 tip B tip AE tip C ostali
cannot work properly without food.
ne more pravilno delovati.
can be combined with anti-HIV medicines belonging to another class [e.g. NRTIs (nucleoside reverse transcriptase inhibitors), NNRTIs (non-nucleoside reverse transcriptase inhibitors), CCR5 antagonists and FIs (fusion inhibitors)].
lahko uporablja skupaj z drugimi zdravili proti HIV, ki spadajo v druge skupine [npr. NRTI (nukleozidni zaviralci reverzne transkriptaze), NNRTI (nenukleozidni zaviralci reverzne transkriptaze), antagonisti CCR5 in FI (zaviralci fuzije)].
and cobicistat or ritonavir.
in kobicistat ali ritonavir.
If you belong to this age group, please discuss with your doctor if you can use Darunavir Krka d.d..
Če sodite v to starostno skupino, se s svojim zdravnikom pogovorite, ali lahko uporabljate zdravilo Darunavir Krka d.d..
tablets the child must take.
mora otrok zaužiti.
muscle pain, tenderness or weakness.
To so: - mišične bolečine, občutljivost ali šibkost.
with food and drink See section 3 ‘How to take Darunavir Krka d.d..'
skupaj s hrano in pijačo Glejte poglavje 3 "Kako jemati zdravilo Darunavir Krka d.d.
and ritonavir two times per day or once a day.
in ritonavirja mora otrok zaužiti dvakrat na dan ali enkrat na dan.
400 or 800 milligram tablet is not for use in children younger than 3 years of age or weighing less than 40 kilograms.
po 400 ali 800 mg se ne smejo uporabljati pri otrocih, mlajših od 3 let ali s telesno maso manj kot 40 kg.
600 mg tablets.
600 mg tablete.
is used to treat adults and children of 3 years of age and above, and at least 15 kilogram body weight who are infected by HIV and who have already used other antiretroviral medicines.
uporabljamo za zdravljenje odraslih in otrok, starih 3 leta ali več in s telesno maso najmanj 15 kg, ki so okuženi z virusom HIV in so že prejemali druga protiretrovirusna zdravila.
Population pharmacokinetic analysis in HIV infected patients showed that darunavir pharmacokinetics are not considerably different in the age range (18 to 75 years) evaluated in HIV infected patients (n=12, age ≥ 65) (see section 4.4).
StarostnikiPopulacijska analiza farmakokinetike pri bolnikih, okuženih s HIV, je pokazala, da farmakokinetika darunavirja ni bistveno drugačna v razponu starosti, ki so ga proučevali pri bolnikih, okuženih s HIV (od 18 do 75 let) (n = 12, starost ≥ 65) (glejte poglavje 4.4).
Baseline genotype or phenotype and virologic outcome Baseline genotype and darunavir FC (shift in susceptibility relative to reference) were shown to be a predictive factor of virologic outcome.
Začetni genotip ali fenotip in virološki izid Začetni genotip in FC darunavirja (stopnja spremembe občutljivosti glede na referenco) sta dejavnika, ki nakazujeta virološki izid.
contains the active substance darunavir.
vsebuje učinkovino darunavir.
always together with ritonavir.
vedno zaužiti skupaj z ritonavirjem.
and ritonavir without talking to your doctor.
in ritonavirja, ne da bi se posvetovali s svojim zdravnikom.
The direction of the arrow for each pharmacokinetic parameter is based on the 90% confidence interval of the geometric mean ratio being within (↔), below (↓) or above (↑) the 80-125% range (not determined as “ND”).
Smer puščice je za vsak farmakokinetični parameter določena na osnovi 90 % intervala zaupanja geometričnega povprečnega razmerja, ki je znotraj (↔), pod (↓) ali nad (↑) območjem 80-125% spremembe (ni podatka je prikazano z "ND").
tablets is right for the child.
primerne za otroka.
Your doctor should do blood tests before you start Darunavir Krka d.d..
Zdravnik bo opravil krvne preiskave, preden začnete jematizdravilo Darunavir Krka d.d..
Even if you feel better, do not stop taking Darunavir Krka d.d.
Tudi če se počutite bolje, ne smete prenehati z jemanjem zdravila Darunavir Krka d.d.
Imputations according to the TLOVR algorithm Last Observation Carried Forward imputation 95% confidence intervals.
pripisane vrednosti, izračunane z uporabo algoritma TLOVR pripis zadnje izmerjene vrednosti (LOCF - Last Observation Carried Forward) 95 % intervali zaupanja
is not for use in children younger than 3 years of age or weighing less than 15 kilograms.
se ne sme uporabljati pri otrocih, mlajših od 3 let ali s telesno maso manj kot 15 kg.
Driving and using machines Do not operate machines or drive if you feel dizzy after taking Darunavir Krka d.d..
Vpliv na sposobnost upravljanja vozil in strojev Ne upravljajte strojev in ne vozite avtomobila, če ste po jemanju zdravila Darunavir Krka d.d.
This dose must not exceed the recommended adult dose, which is 800 milligram Darunavir Krka d.d.
Ta odmerek ne sme preseči priporočenega odmerka za odrasle, ki je 800 mg zdravila Darunavir Krka d.d.
There are some medicines that you must not combine with Darunavir Krka d.d..
Obstajajo določena zdravila, ki jih ne smete kombinirati z zdravilom Darunavir Krka d.d..
The increased exposure to darunavir in HIV-1 infected patients compared to healthy subjects may be explained by the higher concentrations of α1-acid glycoprotein (AAG) in HIV-1 infected patients, resulting in higher darunavir binding to plasma AAG and, therefore, higher plasma concentrations.
Zvečana izpostavljenost darunavirju pri bolnikih, okuženih s HIV-1 v primerjavi z zdravimi preiskovanci lahko razložimo z višjimi koncentracijami alfa-1 kislega glikoproteina (AAG) pri bolnikih, okuženih s HIV-1, kar je povzročilo večjo vezavo darunavirja na plazemski AAG in zato večje plazemske koncentracije.
Based upon the findings, the carbamazepine dose may need to be reduced by 25% to 50% in the presence of darunavir/ritonavir.
Na podlagi ugotovitev bo v prisotnosti zdravil darunavir/ritonavirmorda treba odmerkekarbamazepina zmanjšati za 25 % do 50 %.
Dose(twice daily with food)
Odmerek (enkrat na dan Odmerek (dvakrat na s hrano)
This guidance is based on the half-life of darunavir in the presence of cobicistat or ritonavir and the recommended dosing interval of approximately 24 hours.
To navodilo temelji na razpolovnem času darunavirja v prisotnosti kobicistata ali ritonavirja in na priporočenem režimu odmerjanja na približno 24 ur.
If youtake more Darunavir Krkad.d.than you should Contact your doctor, pharmacist or nurse immediately.
Če ste vzeli večji odmerek zdravila Darunavir Krka d.d., kot bi smeli Nemudoma pokličite svojega zdravnika, farmacevta ali medicinsko sestro.
with ritonavir unless specifically directed by the doctor.
skupaj z ritonavirjem, razen če vam jemanje izrecno naroči vaš zdravnik.
Cobicistat inhibits the tubular secretion of creatinine and may cause modest increases in serum creatinine and modest declines in creatinine clearance.
Kobicistat zavira tubulno sekrecijo kreatinina in lahko povzroči zmerno zvišanje serumskega kreatinina ter zmerno zmanjšanje očistka kreatinina.
and cobicistat or ritonavir without talking to your doctor.
in kobicistata ali ritonavirja, ne da bi se posvetovali s svojim zdravnikom.
The dose of cobicistat to be used with darunavir has not been established in this patient population.
Odmerka kobicistata za uporabo z zdravilom darunavir pri tej populaciji niso določili.
and raltegravir (for HIV infection), rashes (generally mild or moderate) may occur more frequently than in patients taking either medicine separately.
skupaj z raltegravirjem (za zdravljenje okužbe z virusom HIV), se izpuščaji lahko pojavijo pogosteje (večinoma blagi do zmerni) kot pri bolnikih, ki teh dveh zdravil ne jemljejo skupaj.
Outcomes at week 48
Izidi po 48. tednu
400 and 800 milligram tablets are used to treat adults and children (3 years of age and above, at least 40 kilograms body weight) who are infected by HIV and who have not used antiretroviral medicines before.
po 400 in 800 mg uporabljamo za zdravljenje odraslih in otrok (starih 3 leta ali več in s telesno maso najmanj 40 kg), ki so okuženi z virusom HIV in - še niso prejemali nobenega drugega protiretrovirusnega zdravila.
Cobicistat as a pharmacokinetic enhancer of darunavir should, therefore, not be initiated in patients with creatine clearance less than 70 ml/min if any co-administered agent requires dose adjustment based on creatinine clearance: e.g. emtricitabine, lamivudine, tenofovir disoproxil (as fumarate, phosphate or succinate) or adefovir dipovoxil.
Kobicistata kot farmakokinetičnega ojačevalca darunavirja ne smete uvesti bolnikom z očistkom kreatinina manj kot 70 ml/min, če je treba odmerek katere izmed sočasno danih učinkovin prilagajati na osnovi očistka kreatinina (npr. emtricitabin, lamivudin, dizoproksiltenofovirat (v obliki fumarata, fosfata ali sukcinata) ali adefovirdipivoksilat).
HEPATITIS C VIRUS (HCV) DIRECT-ACTING ANTIVIRALS NS3-4A protease inhibitors
PROTIVIRUSNA ZDRAVILA ZNEPOSREDNIMDELOVANJEMNA VIRUSHEPATITISA C Zaviralci serinske proteaze NS3 4A elbasvir/grazoprevir
600 mg tablets can be used to construct the twice daily 600 mg regimen.
600 mg tablete lahko uporabljate za režim odmerjanja 600 mg dvakrat na dan.
ENDOTHELIN RECEPTOR ANTAGONISTS Bosentan
ANTAGONISTIENDOTELINSKIH RECEPTORJEV bosentan
INTERACTIONS AND DOSE RECOMMENDATIONS WITH OTHER MEDICINAL PRODUCTS Medicinal products by therapeutic areas
MEDSEBOJNA DELOVANJA Z DRUGIMI ZDRAVILI IN PRIPOROČILA ZA ODMERJANJE Zdravilapoterapevtskihpodročjih Medsebojnodelovanje
PHOSPHODIESTERASE, TYPE 5 (PDE-5) INHIBITORS For the treatment of erectile dysfunction
ZAVIRALCI FOSFODIESTRAZE TIPA 5 (PDE-5) Za zdravljenje motenj erekcije avanafil sildenafil tadalafil vardenafil
withany of the following medicines If you are taking any of these, ask your doctor about switching to another medicine.
Če jemljete katero od naštetih zdravil, prosite zdravnika, naj vam predpiše drugo zdravilo.